Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Top Cited Papers
- 1 May 2012
- journal article
- practice guideline
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (13), 1553-1561
- https://doi.org/10.1200/jco.2011.39.9436
Abstract
Purpose: To provide recommendations for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer. Methods: The American Society of Clinical Oncology convened a Panel of experts in medical and gynecologic oncology, clinical pharmacology, pharmacokinetics and pharmacogenetics, and biostatistics and a patient representative. MEDLINE searches identified studies published in English between 1996 and 2010, and a systematic review of the literature was conducted. A majority of studies involved breast, ovarian, colon, and lung cancers. This guideline does not address dosing for novel targeted agents. Results: Practice pattern studies demonstrate that up to 40% of obese patients receive limited chemotherapy doses that are not based on actual body weight. Concerns about toxicity or overdosing in obese patients with cancer, based on the use of actual body weight, are unfounded. Recommendations: The Panel recommends that full weight–based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure. There is no evidence that short- or long-term toxicity is increased among obese patients receiving full weight–based doses. Most data indicate that myelosuppression is the same or less pronounced among the obese than the non-obese who are administered full weight–based doses. Clinicians should respond to all treatment-related toxicities in obese patients in the same ways they do for non-obese patients. The use of fixed-dose chemotherapy is rarely justified, but the Panel does recommend fixed dosing for a few select agents. The Panel recommends further research into the role of pharmacokinetics and pharmacogenetics to guide appropriate dosing of obese patients with cancer.Keywords
This publication has 95 references indexed in Scilit:
- Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard careBritish Journal of Cancer, 2010
- The Obesity Epidemic in the United States Gender, Age, Socioeconomic, Racial/Ethnic, and Geographic Characteristics: A Systematic Review and Meta-Regression AnalysisEpidemiologic Reviews, 2007
- International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiencyEuropean Journal Of Cancer, 2007
- Relation between chemotherapy dose, oestrogen receptor expression, and body-mass indexThe Lancet, 2005
- Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapyEuropean Journal Of Cancer, 2004
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- Optimising chemotherapy dose density and dose intensity: new strategies to improve outcomes in adjuvant therapy for breast cancerEuropean Journal Of Cancer, 2000
- A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient careEuropean Journal Of Cancer, 2000
- Chemotherapy dose reduction and delay in clinical practiceEuropean Journal Of Cancer, 2000
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995